Predicted protein targets (top 4)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | GPR119 | Q8TDV5 | 13/20 | 0.53 |
| ▸ | HPGD | P15428 | 1/20 | 0.49 |
| ▸ | RECQL | P46063 | 1/20 | 0.47 |
| ▸ | EPHX1 | P07099 | 1/20 | 0.47 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL26098762 | 1.00 | GPR119 (0.53) | GPR119HPGDRECQLEPHX1 | |
| SCHEMBL26099289 | 1.00 | GPR119 (0.53) | GPR119HPGDRECQLEPHX1 | |
| SCHEMBL118561 | 0.92 | GPR119 (0.57) | GPR119HPGDRECQLEPHX1 | |
| SCHEMBL31561507 | 0.91 | GPR119 (0.51) | GPR119HPGDRECQLEPHX1 | |
| SCHEMBL26121663 | 0.91 | GPR119 (0.51) | GPR119HPGDRECQLEPHX1 | |
| SCHEMBL24364944 | 0.91 | GPR119 (0.48) | GPR119HPGD | |
| SCHEMBL14971262 | 0.91 | GPR119 (0.48) | GPR119HPGD | |
| SCHEMBL26543757 | 0.91 | GPR119 (0.45) | GPR119HPGDRECQLEPHX1 | |
| Hydrochloric Acid SCHEMBL7362824 | 0.91 | GPR119 (0.56) | GPR119HPGDRECQLEPHX1 | |
| Hydrochloric Acid SCHEMBL6981419 | 0.91 | GPR119 (0.56) | GPR119HPGDRECQLEPHX1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20250051338-A1 | TYK2 DEGRADERS AND USES THEREOF | KYMERA THERAPEUTICS, INC. | 2025-02-13 | — | — | US | disclosed |
| CN-119013277-A | TYK2 degrading agent and application thereof | 凯麦拉医疗公司 | 2024-11-22 | — | — | CN | disclosed |
| EP-4423086-A1 | TYK2 DEGRADERS AND USES THEREOF | Kymera Therapeutics, Inc. (US) | 2024-09-04 | — | — | EP | disclosed |
| WO-2023076161-A1 | TYK2 DEGRADERS AND USES THEREOF | KYMERA THERAPEUTICS, INC. (US) | 2023-05-04 | — | — | WO | disclosed |
| WO-2023076161-A1 | TYK2 DEGRADERS AND USES THEREOF | KYMERA THERAPEUTICS, INC. (US) | 2023-05-04 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20250051338-A1 | TYK2 DEGRADERS AND USES THEREOF | TYK2, DYRK2, DYRK1A | GPR119 3223/4885HPGD 4054/4885RECQL 2166/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.